Personalis Cancer Assay NeXT Personal Ranks #1 on The Scientist’s Top 10 Innovations of 2022
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. today announced its NeXT Personal® cancer assay earned the top spot on The Scientist’s Top 10 Innovations of 2022 list. NeXT Personal detects, quantifies, and monitors circulating tumor DNA (ctDNA) to catch molecular residual disease (MRD) following surgery and to track response to therapy. The…
